Cystic fibrosis (CF) is a rare, life-threatening, genetic disease
that affects between 70,000 and 100,000 patients worldwide. In the US
and UK, average life expectancy is 35 to 40 years old. In countries
such as El Salvador, India and Bulgaria, life expectancy drops to
below 15. There currently is no cure for CF. We are currently
evaluating investigational compounds in early clinical phases for a
triple combination therapy.
Diabetic nephropathy, or diabetic kidney disease, is a common
complication of diabetes and the leading cause of chronic kidney
disease in the developing world. We are currently conducting a
clinical study to assess the effects of an investigational drug on
progression of kidney disease in patients with state 2 to 4 CKD and
type 2 diabetes.